Clinical trials: Platinum Sensitive Ovarian Cancer
Ovarian Neoplasms, Platinum Sensitive Ovarian Cancer
A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study of niraparib as maintenance in platinum sensitive ovarian cancer patients who have either gBRCAmut or a tumor with high-grade serous histology and…
- Trial name
- NCT01847274
- Testing
- Active comparator: Niraparib
- Where
- 112 sites in United States, Austria and 13 more
- Volunteers
- 596 people
- Sponsor
- Tesaro, Inc.
Ovarian Cancer, Fallopian Tube Cancer
Feasibility Trial of Intraperitoneal Chemotherapy for Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma
The purpose of this study is to evaluate giving chemotherapy drugs directly into the abdomen (belly) along with intravenous administration.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Uterine Cancer
- Trial name
- NCT00582205
- Testing
- Paclitaxel, Cisplatin IP
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Oklahoma
Ovarian Cancer, Fallopian Tube Cancer
A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II)
Part 1 (Completed Enrollment) - The purpose of the first part of the study was to evaluate the safety of different doses and dosing regimens of oral rucaparib administered daily to patients with solid tumors.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Advanced Solid Tumor With Evidence of Germline or Somatic BRCA
- Trial name
- NCT01482715
- Testing
- Rucaparib
- Where
- 16 sites in United States, Canada and 3 more
- Volunteers
- 136 people
- Sponsor
- pharmaand GmbH
Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments
Comparison of olaparib vs. physician's choice of single agent standard of care non-platinum based chemotherapy in patients with germline Breast Cancer susceptibility gene (gBRCA) mutated ovarian cancer who have progressed at…
- Trial name
- SOLO3 (NCT02282020)
- Testing
- OLAPARIB, Single agent chemotherapy
- Where
- 94 sites in United States, Argentina and 11 more
- Volunteers
- 266 people
- Sponsor
- AstraZeneca
Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma
Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This phase III trial studies olaparib or cediranib maleate and olaparib to see how well they work compared with standard platinum-based chemotherapy in treating patients with platinum-sensitive ovarian, fallopian tube, or primary…
- Conditions
- Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Ovarian Clear Cell Adenocarcinoma
- Trial name
- NCT02446600
- Testing
- Biospecimen Collection, Carboplatin, Cediranib Maleate
- Where
- 356 sites in United States, Canada and 2 more
- Volunteers
- 579 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Cancer, Peritoneal Neoplasms
Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer
The purposes of this study are: 1. To determine the dose limiting toxicity (DLT) and the maximum tolerated dose (MTD) weekly of topotecan in combination with standard dose gefitinib in patients with relapsed, platinum-resistant…
- Conditions
- Ovarian Cancer, Peritoneal Neoplasms, Fallopian Tube Cancer
- Trial name
- NCT00317772
- Testing
- Topotecan, Gefitinib
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- M.D. Anderson Cancer Center
Ovarian Cancer, Fallopian Tube Cancer
Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy
The purpose of this study is to determine if an investigational drug called MORAb-003 is useful by itself or when used with other approved cancer drugs in treating women with ovarian cancer.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms
- Trial name
- NCT00318370
- Testing
- Farletuzumab, Chemo Plus Far
- Where
- 20 sites in United States, Germany
- Volunteers
- 58 people
- Sponsor
- Morphotek
Ovarian Cancer
Caelyx Biweekly in Heavily Pretreated Patients With Relapsed Ovarian Cancer
Effect of biweekly schedule of PLD on dose-limiting toxicity of PPE and patient's quality of life
- Trial name
- NCT00170573
- Testing
- Caelyx
- Volunteers
- 77 people
- Sponsor
- North Eastern German Society of Gynaecological Oncology
Ovarian Cancer, Fallopian Tube Cancer
Carboplatin/Pralatrexate in Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer
Pralatrexate is a type of antifolate drug which means is restrains the production of folic acid in the body. Folic acids are used by tumors to increase tumor cell growth and division.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Trial name
- NCT01188876
- Testing
- carboplatin, pralatrexate, Folic Acid
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Massachusetts General Hospital
Platinum Sensitive, BRCA Mutated
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
A Phase III, randomised, double-blind, placebo-controlled, multi-centre study to assess the efficacy of olaparib maintenance monotherapy in relapsed high grade serous ovarian cancer (HGSOC) patients (including patients with…
- Conditions
- Platinum Sensitive, BRCA Mutated, Relapsed Ovarian Cancer, Following Complete or Partial Response to Platinum Based Chemotherapy
- Trial name
- NCT01874353
- Testing
- Olaparib 300mg tablets
- Where
- 126 sites in United States, Australia and 15 more
- Volunteers
- 327 people
- Sponsor
- AstraZeneca
Fallopian Tube Cancer, Ovarian Cancer
Consolidation Therapy With Hu3S193 for Women With Ovarian, Primary Peritoneal or Fallopian Tube Cancer
RATIONALE: Monoclonal antibodies, such as Hu3S193, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
- Trial name
- NCT01137071
- Testing
- Monoclonal antibody Hu3S193
- Where
- 8 sites in Brazil
- Volunteers
- 29 people
- Sponsor
- Recepta Biopharma
Ovarian Cancer
Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse
This research is being done to find out if Carboplatin and Taxane works better alone or when given with an experimental drug called MORAb-003(farletuzumab) in subjects with first platinum sensitive relapsed ovarian cancer.
- Trial name
- NCT00849667
- Testing
- Farletuzumab, Carboplatin, Taxane
- Where
- 375 sites in United States, Argentina and 28 more
- Volunteers
- 1,100 people
- Sponsor
- Morphotek
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
Pemetrexed and Carboplatin in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
This phase II trial studies how well pemetrexed disodium and carboplatin work in treating patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer.
- Conditions
- Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Trial name
- NCT01001910
- Testing
- Carboplatin, Laboratory Biomarker Analysis, Pemetrexed Disodium
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- Albert Einstein College of Medicine
Ovarian Cancer, Peritoneal Carcinomatosis
Olvi-Vec Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer
The purpose of this study is to determine if Olvi-Vec oncolytic immunotherapy is well tolerated with anti-tumor activity in patients diagnosed with recurrent or refractory ovarian cancer and peritoneal carcinomatosis.
- Conditions
- Ovarian Cancer, Peritoneal Carcinomatosis, Fallopian Tube Cancer
- Trial name
- NCT02759588
- Testing
- Olvi-Vec, Platinum-doublet with or without bevacizumab
- Where
- 2 sites in United States
- Volunteers
- 46 people
- Sponsor
- Genelux Corporation
Ovarian Cancer, Fallopian Tube Cancer
European Trial on Enhanced DNA Repair Inhibition in Ovarian Cancer
This study will be performed in women with platinum-sensitive, high-grade serous, high-grade endometrioid, undifferentiated epithelial ovarian cancer, carcinosarcoma, fallopian tube or primary peritoneal cancer (proven by central…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
- Trial name
- EUDARIO (NCT03783949)
- Testing
- Ganetespib, Niraparib, Carboplatin
- Where
- 13 sites in Austria, Belgium and 3 more
- Volunteers
- 122 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Ovarian Neoplasms, Peritoneal Neoplasms
BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Cancer
This phase I, open label dose escalation study will investigate the addition of BIBF 1120 to treatment with the combination of carboplatin and Pegylated Liposomal Doxorubicin (PLD) in patients with advanced, platinum sensitive…
- Trial name
- NCT01314105
- Testing
- BIBF 1120 + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min, BIBF 1120+ PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min
- Where
- 3 sites in Spain
- Volunteers
- 19 people
- Sponsor
- Boehringer Ingelheim
Recurrent Ovarian Cancer, Platinum Sensitive Ovarian Cancer
Slowed Carboplatin Infusion for Ovarian Cancer Patients Receiving Carboplatin Re-Treatment
This is a research study to determine if administering carboplatin at a slower rate when re-treating recurrent ovarian cancer patients prior to the development of a hypersensitivity reaction will decrease the frequency and…
- Trial name
- NCT02035345
- Testing
- Carboplatin
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Massachusetts General Hospital
Ovarian Cancer
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
The purpose of this study is to compare the progression-free survival of two treatment regimens for relapsed ovarian cancer.
- Trial name
- NCT00090610
- Testing
- Docetaxel, Carboplatin
- Where
- 19 sites in United States
- Volunteers
- 150 people
- Sponsor
- Duke University
Epithelial Ovarian Cancer, Fallopian Tube Cancer
A Study LY2228820 for Recurrent Ovarian Cancer
A study for women with ovarian cancer that has returned at least 6 months after platinum-based chemotherapy.
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT01663857
- Testing
- LY2228820, Carboplatin, Gemcitabine
- Where
- 30 sites in United States, Australia and 2 more
- Volunteers
- 118 people
- Sponsor
- Eli Lilly and Company
Ovarian Neoplasms
Dose Escalation Study of BIBF 1120 in Combination With Carboplatin and PLD in Relapsed Ovarian Cancer (OC)
This phase I, open label dose escalation study will investigate the addition of BIBF 1120 to treatment with the combination of carboplatin and Pegylated Liposomal Doxorubicin (PLD) in patients with advanced, platinum sensitive…
- Trial name
- NCT01329549
- Testing
- BIBF 1120 (high) + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min, BIBF 1120 (medium) + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min, BIBF 1120 (low) + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min
- Where
- 3 sites in Japan
- Volunteers
- 2 people
- Sponsor
- Boehringer Ingelheim